Page 17 - Aurobindo Pharma

Aurobindo named in a lawsuit for selling adulterated irbesartan products

In October, Aurobindo Pharma announced a voluntary recall of 22 batches of irbesartan due to the detection of trace amounts of NDEA

Aurobindo Pharma hits 52-week high; up 56% in six months

The stock hit a 52-week high of Rs 830, up 3%, surging 55% in past six months, as compared to 3% rise in the S&P BSE Sensex.

Improving margins, reducing debt key challenges for Aurobindo Pharma

While revenue growth is expected to be strong, improving margins and reducing debt could be challenging

Aurobindo Pharma to launch oncology, respiratory products in US by 2021

The company is also planning to launch first set of biosimilars and vaccines in growth markets during this time, Aurobindo Pharma said in an investor presentation

Aurobindo expects drug filing opportunities in US to stay for another 5 yrs

The senior management of Aurobindo said they are looking at launching the Oncology products in the US market by the end of this year

Aurobindo inks pact to acquire Australian pharma firm for $12.5 mn

Based out of Melbourne, Advent Pharmaceuticals is engaged in developing and commercialising generic inhaled medicines for global markets.

Aurobindo Pharma slips 4% post Q2 nos; Credit Suisse, Citi remain bullish

The company reported a 21.7 per cent decline in net profit at Rs 6.11 billion for the quarter ended September 2018, owing to rise in costs.

Aurobindo Pharma reports 21.7 per cent decline in profit, says expenses up

The company was able to improve its US formulations revenues by 6.1 per cent year-on-year at Rs 22.27 billion.

Aurobindo recalls 22 batches of hypertensive drug in US citing cancer risk

According to a notification by the American drug regulator on its website, these 22 batches of Irbesartan drug substance were supplied by the city-based Aurobindo to ScieGen Pharmaceuticals Inc

Aurobindo Pharma scouting for suitable acquisitions in domestic market

Recently, through the acquisition of Sandoz's dermatology and oral solids business, Aurobindo has now entered the branded OTC segment in the US

Aurobindo Pharma buys Sandoz's US business in $900 million deal

The deal gives the Hyderabad based company access to Sandoz's portfolio of oral solids and dermatology drugs and manufacturing footprint

Aurobindo's US operations get growth boost; stock up 9% on Sandoz deal

Attractive valuations, large portfolio add to growth pipeline, keep leverage ratios moderate

Aurobindo Pharma gains 5% on acquisition of Sandoz's US business

The stock rallied 5% to Rs 732 on Thursday, extending its Wednesday's 2% gain on the BSE, after the company announced the acquisition of Sandoz's generic business in the US for $900 million.

Aurobindo Pharma drops plan to buy speciality generics biz of Mallinckrodt

Aurobindo was looking to acquire it for $800 million or so

Growth in key markets perks up Aurobindo stock, earnings to increase

On the flip side, Aurobindo may have seen some pressure on margins led by one-offs as product recall/provisions and some impact on higher raw-material prices

Aurobindo Pharma Q1 net profit slips 12% to Rs 4.5 bn over rising expenses

Total expenses of the company for the first quarter were Rs 37.23 billion, compared to Rs 29.92 billion in the same period last fiscal

Apotex acquisition likely to reduce Aurobindo's dependence on US market

The Apotex acquisition will further strengthen Aurobindo's position among the top 10 pharma companies by sales in Europe

Apotex buy may not initially contribute to Aurobindo's earnings

Unlikely to add to profits in first 2 years; working capital may rise

Aurobindo pharma likely to clinch Mallinckrodt deal for $800 mn this July

Street cautious as Mallinckrodt biz is declining amid enhanced scrutiny on opioid drugs

Aurobindo Pharma gets USFDA nod for pain reliever Ibuprofen; launch in Sept

Quoting Nielsen data, Aurobindo Pharma said the estimated market size of ibuprofen capsules OTC is $164 million for the twelve months ending March 2018